Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Disc Medicine (NASDAQ:IRON) and maintained a price target of $85.
May 28, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Disc Medicine and maintained a price target of $85, indicating strong confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $85 by a reputable analyst suggests strong confidence in Disc Medicine's future performance. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100